Nobel Prize Awarded for Optogenetics, a Mental Health Research Breakthrough

The 2026 Nobel Prize in Physiology or Medicine was awarded to three scientists for pioneering optogenetics, a technique using light to control nerve cells. The Nobel Assembly at the Karolinska Institute in Stockholm announced the award to Karl Deisseroth, Peter Hegemann, and Georg Nagel on Monday, recognizing research it said fundamentally alters the understanding of the brain.

Per Svenningsson, chair of the Nobel Committee for Physiology or Medicine, said, "Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of." The committee praised the trio for laying the foundation of a new era in neuroscience, noting its specific relevance to neurological and psychiatric disorders. Each laureate will receive an equal share of the prize money, which totals 12 million Swedish kronor.

How optogenetics works and its origins

Optogenetics uses light-sensitive proteins from algae to control individual nerve cells, enabling precise study of brain function and behavior. The technique allows researchers to switch specific neural circuits on or off using light. This lets scientists bring memories to life, create feelings, drive behaviors, and study neurons involved in psychiatric and neurological disorders.

The research began with Peter Hegemann's work in the early 1990s on the microscopic alga Chlamydomonas. He discovered the algae could sense light and react in half a millisecond. Hegemann hypothesized a single protein was responsible for both capturing light and acting as an ion channel. He later teamed with Georg Nagel to research these proteins, including channelrhodopsin-2, confirming the hypothesis.

They introduced the gene for channelrhodopsin-2 into embryonic human kidney cells, which then produced an electrical signal when exposed to light. Separately, Karl Deisseroth was searching for a protein to trigger electrical impulses in nerve cells to better understand brain function. Deisseroth obtained DNA from Nagel, introduced it to rat nerve cells, and unlocked the potential for controlling nerve cells in live animals using blue light.

Clinical progress in vision restoration and mental health applications

Optogenetics is advancing in clinical trials for blindness and shows promise for treating psychiatric disorders by targeting specific neural circuits. Researchers are using it in trials to restore sight in people with visual impairment due to retinitis pigmentosa. In a phase 3 trial, optogenetic therapy demonstrated clinically meaningful improvements in visual acuity, meeting its clinical endpoint for improving sight in patients with ultra-low vision. The company behind the research, Nanoscope Therapeutics, is now seeking FDA approval.

Lejla Vajzovic, director of the Duke Surgical Vitreoretinal Fellowship Program, said optogenetics offers a fundamentally different approach to vision restoration. She explained it could make surviving retinal cells light-sensitive and create a new pathway for visual information. Vinit Mahajan, professor of ophthalmology at Stanford University, called it a technological triumph. He said ophthalmology is setting a precedent for the rest of medicine in using bioengineered proteins to make people healthy.

For mental health, the second phase of two trials grounded in indirect optogenetics-one into autism and one into schizophrenia-has been completed. Deisseroth, a US psychiatrist and neurologist, said the key point is that this provides, for the first time in psychiatry, a true cellular causality understanding for symptoms.

Laureate backgrounds and scientific collaboration

The prize winners built on decades of collaborative research that began with algal light-sensing proteins. Karl Deisseroth is a physician-scientist with Stanford University and an investigator with the Howard Hughes Medical Institute. Peter Hegemann is the Hertie senior professor of neuroscience at Humboldt University in Berlin. Georg Nagel, 73, is a biophysics professor at the University of Wurzburg.

Future implications for neuroscience and treatment

Optogenetics opens new pathways for understanding the brain as a dynamical system and could lead to broad therapeutic advances. Deisseroth told Healio that optogenetics can be applied to almost anything and allows thinking about the entire brain as a dynamical system. There is hope it can eventually lead to treatments for a wide range of mental health disorders.

Vajzovic highlighted the potential for a mutation-agnostic approach, where a single therapy could benefit patients with many different causes of retinal degeneration. Moving forward, she said the focus must be on improving the quality and resolution of restored vision and demonstrating meaningful improvements in patients’ everyday lives. Nanoscope Therapeutics is seeking FDA approval for its optogenetic therapy after phase 3 trials showed clinically meaningful improvements in visual acuity for patients with ultra-low vision.